Submitted by amarin on Mon, 10/27/2025 - 12:01 Home News Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibr… ID Reference 25076 Tags General Releases Page Tags Global News / Press Release News & Media News title Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
